Stock Story -
Skincare company BeautyHealth (NASDAQ:SKIN) will be reporting results tomorrow after market hours. Here's what investors should know.
BeautyHealth beat analysts' revenue expectations by 10.5% last quarter, reporting revenues of $96.8 million, down 1.4% year on year. It was a weak quarter for the company, with revenue guidance for the next quarter falling below Wall Street's expectations.
Is BeautyHealth a buy or sell going into earnings? Find out by reading the original article on StockStory, it's free.
This quarter, analysts are expecting BeautyHealth's revenue to decline 6.5% year on year to $80.65 million, a reversal from the 14.4% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.09 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BeautyHealth has missed Wall Street's revenue estimates twice over the last two years.
Looking at BeautyHealth's peers in the personal care segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Coty (NYSE:COTY) delivered year-on-year revenue growth of 7.5%, meeting analysts' expectations, and Inter Parfums (NASDAQ:IPAR) reported revenues up 3.9%, falling short of estimates by 1.4%. Coty traded down 3.6% following the results.
Read the full analysis of Coty's and Inter Parfums's results on StockStory.
Investors in the personal care segment have had steady hands going into earnings, with share prices flat over the last month. BeautyHealth is down 13% during the same time and is heading into earnings with an average analyst price target of $4.5 (compared to the current share price of $3.35).
